New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymosin Beta-4 vs MOTS-c

Thymosin Beta-4 vs MOTS-c

Side-by-side comparison of key properties, dosing, and research.

Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4
Anti-Aging & Longevity
MOTS-c
Summary
Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
Half-Life
Not well characterized; likely similar to TB-500 (~1–2 hours)
Estimated 1–2 hours
Admin Route
SubQ, IM
SubQ
Research
Typical Dose
5–10 mg
5–15 mg
Frequency
2x per week (loading), then 1x per week (maintenance)
3–5 times per week
Key Benefits
  • Systemic tissue repair and regeneration
  • Promotes cardiac recovery after myocardial infarction
  • Hair follicle regeneration and anti-hair-loss
  • Anti-inflammatory (systemic)
  • Wound healing acceleration
  • Neuroprotection after brain injury
  • Protects against ischemia-reperfusion injury
  • Anti-aging at cellular level
  • Synergizes powerfully with BPC-157
  • Improves insulin sensitivity and glucose metabolism
  • Enhances exercise capacity and endurance
  • Reduces age-related metabolic decline
  • Activates AMPK — the master metabolic regulator
  • Promotes fat oxidation
  • Anti-inflammatory effects
  • May extend healthspan via mitochondrial optimization
  • Increases energy and reduces fatigue
Side Effects
  • Generally very well tolerated
  • Injection site reactions
  • Mild fatigue at initiation (repair signaling)
  • Rare: mild inflammatory response
  • +1 more
  • Injection site irritation
  • Fatigue during initial adaptation
  • Unknown long-term profile (limited human data)
Stacks With